Today on Drug Discovery & Development
How Dotmatics aims to help reduce the drug discovery failure rate
It’s clear that drug discovery and development costs have rapidly increased in recent decades. That said, estimates vary widely. For example, a 2020 article in JAMA noted that estimates range from $314 million to $2.8 billion. A high drug discovery failure rate exacerbates the problem. Part of the challenge of making such calculations is the…
Women in Pharma: CRB’s Director of Digital Technology on why the pharma industry is captivating
Yvonne Duckworth, CRB’s director of digital technology, says she was fortunate to enter the pharmaceutical industry straight out of college. “My first job, 31 years ago, was a wonderful opportunity as an automation engineer with an engineering company servicing the pharmaceutical industry,” she said. Duckworth has maintained her pharma focus at CRB, where she has…
Drug Discovery and Development See More >
Cardinal Health’s CFO to move up to corner office
Cardinal Health (NYSE: CAH) announced today that its board has elected CFO Jason Hollar to become the pharma and medtech giant’s new chief executive officer, effective Sept. 1. Hollar will succeed Mike Kaufmann, who has been Dublin, Ohio–based Cardinal Health’s CEO for the past five years. The CEO transition comes as Cardinal Health continues efforts…
Sponsored Content See More >
Using Real-World Data to Address COVID-19By Cheryl Reifsnyder, PhD As a leading provider of data and advanced analytics, Veradigm understands the critical role real-world data…
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
How Seer aims to remove technological barriers to studying the proteome
Founded in 2017, the proteomics company Seer (Nasdaq:SEER) is building up a growing roster of customers, including pharma and biotech companies, translational and academic labs and CROs. Applications of its technology include biomarker discovery, target identification and multiomics research for cancer or other complex disease detection. Recently, Weill Cornell Medicine and privately-held SpaceX used Seer’s…
Infectious Disease See More >
A next-gen vaccine that could help end COVID-19 whack-a-mole
COVID-19 is an emerging focus for EpicentRx, a private biotech focused on multiple immune-mediated disorders. The La Jolla, California–based company is developing a next-gen COVID vaccine for SARS-CoV-2 based on nucleocapsid rather than spike protein. The recombinant replication-competent adenoviral vaccine that expresses the SARS-CoV-2 nucleocapsid protein could be more resistant to COVID-19 variants. The real-world…
Oncology See More >
FDA approves Enhertu for HER2-low breast cancer
The HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has won FDA approval for patients with unresectable or metastatic HER2-low breast cancer. Enhertu, a HER2-directed antibody drug conjugate, is now the first approved therapy for patients with the HER2-low breast cancer subtype. The recent approval covers patients with HER2-low breast cancer if they have had chemotherapy for…
